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Background. Experimental studies and investigations in patients with cardiac diseases
suggest that opioids at clinical concentrations have no important direct effect on
myocardial relaxation and contractility. In vivo data on the effect of remifentanil on
myocardial function in humans are scarce. This study aimed to investigate the effects of
remifentanil on left ventricular (LV) function in young healthy humans by transthoracic
echocardiography (TTE). We hypothesized that remifentanil does not impair systolic,
diastolic LV function, or both.
Methods. Twelve individuals (aged 18–48 yr) without any history or signs of cardiovascular
disease and undergoing minor surgical procedures under general anaesthesia were studied.
Echocardiographic examinations were performed in the spontaneously breathing subjects
before (baseline) and during administration of remifentanil at a target effect-site
concentration of 2 ng ml21 by target-controlled infusion. Analysis of systolic function
focused on fractional area change (FAC). Analysis of diastolic function focused on peak
early diastolic velocity of the mitral annulus (e′) and on transmitral peak flow velocity (E).
Results. Remifentanil infusion at a target concentration of 2 ng ml21 did not affect heart
rate or arterial pressure. There was no evidence of systolic or diastolic dysfunction during
remifentanil infusion, as the echocardiographic measure of systolic function (FAC) was
similar to baseline, and measures of diastolic function remained unchanged (e′) or
improved slightly (E).
Conclusion. Continuous infusion of remifentanil in a clinically relevant concentration did not
affect systolic and diastolic LV function in young healthy subjects during spontaneous
breathing as indicated by TTE.
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echocardiography
Accepted for publication: 14 December 2010
Opioids are often used for induction and maintenance of
anaesthesia or for sedation in patients at cardiovascular
risk on intensive care units, as they are thought to have
few haemodynamic side-effects and are claimed to be
cardioprotective.1 2 Remifentanil is a newer potent opioid
with several distinctive pharmacokinetic properties including
short half-life, due to a unique metabolism by plasma and
tissue esterase, and potency similar to fentanyl.3 Remifenta-
nil has been reported to decrease both heart rate and arterial
pressure during general anaesthesia, which may cause
severe cardiovascular instability in some cases.4–7 It may
affect haemodynamic variables by histamine release or by
inhibitory actions on the autonomous and central nervous
systems resulting in vasodilation and bradycardia.5–9 In
addition, experimental studies indicate that cardiomyocytes
are regulated by opioid receptors (m, d, k). Opioid receptor
stimulation causes direct and indirect functional changes in
the heart and in myocytes.10–12 Therefore, it seems reason-
able to speculate that remifentanil influences systolic and
diastolic left ventricular (LV) function. In vitro studies on
human and animal heart tissue have given conflicting
results regarding a direct myocardial effect of different
opioids. Fentanyl has been shown to decrease myocardial
contractility of isolated rat ventricular myocytes and isolated
human heart tissue,13 14 whereas in other in vitro studies,
different opioids including fentanyl, sufentanil, and remifen-
tanil did not directly impair inotropic and lusitropic properties
of both isolated human and perfused rabbit heart tissue.15 16
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Differences in species,10 study design, and drug concen-
trations may have contributed to the differences between
studies.
Although the clinical relevance of experimental studies is
acknowledged, it is important that these are supported by
direct investigations of the effects of opioids on cardiac func-
tion in humans in vivo. The aim of this study was to investi-
gate the effects of a clinically relevant concentration of
remifentanil on systolic and diastolic LV function in young
healthy individuals. We hypothesized that remifentanil at a
target effect-site concentration of 2 ng ml21 17 would not




After approval by the local ethics committee (Ethikkommis-
sion beider Basel, Basel, Switzerland) and obtaining written
informed consent, 12 individuals (Table 1) undergoing
minor surgical procedures under general anaesthesia were
enrolled. Exclusion criteria were any history or signs of
cardiac, pulmonary, or systemic disease, any medication
with cardiovascular effects or side-effects, age ,18 or .50
yr, and BMI .30 kg m22. No premedication was given.
After arrival in the preoperative area, i.v. access was
established and Ringer’s lactate administered to replace
the fluid deficit caused by overnight fasting. The deficit per
hour of fasting was calculated as follows: 4 ml kg21 h21 for
the first 10 kg of body weight, 2 ml kg21 h21 for the
second 10 kg, and 1 ml kg21 h21 for every additional kilo-
gram. Fifty per cent of the deficit was replaced before the
start of the study. To minimize nausea and vomiting, 4 mg
of tropisetrone (Navobanw, Novartis Pharma, Basel, Switzer-
land) was given to each patient as soon as i.v. access had
been established. Two-lead electrocardiogram with leads II
and V5 and pulse oximetry were monitored continuously,
and arterial pressure was measured non-invasively every 3
min (PCMS Workstation 90308-15-03, SpaceLab Inc.,
Redmond, WA, USA). Simultaneously, bispectral index
(BISTM; Aspect 1000TM, Aspect Medical Systems Inc., Natick,
MA, USA; software version 1.01) was monitored continuously.
Body temperature was measured continuously and kept
above 368C. Hyper- and hypotension, defined as increase
and decrease of .30% from baseline value in mean arterial
pressure, respectively, were treated with i.v. boluses of gly-
ceryl trinitrate (25–50 mg) and phenylephrine (25–50 mg).
Mild tachycardia or bradycardia was not treated, but the
study was continued only if the heart rate recovered to
values between 50 and 90 beats min21.
The first (baseline) TTE was performed with the patient
awake and unpremedicated in a partial left lateral position
to optimize imaging quality. This position was maintained
until the study was finished. After completion of the baseline
TTE, the patient was given oxygen 2–4 litre min21 by a
face mask, and an i.v. infusion of remifentanil (Ultivaw,
GlaxoSmithKline, London, UK) delivered by a target-controlled
infusion system (Orchestra& Base Primera, Fresenius Vial,
Brezins, France) was started. Target concentration of remifen-
tanil was increased stepwise by 0.5 ng ml21. The second TTE
was performed as soon as a calculated remifentanil target
concentration of 2.0 ng ml2117 (corresponding to an infusion
rate of 0.08–0.09 mg kg21 min21) and stable haemodynamics
had been reached. Stable haemodynamicswere predefined as
,5% variation of mean arterial pressure and heart rate over
three consecutive measurements performed within 6 min.
When the second TTE was finished, the study protocol was
completed.
Doppler echocardiography
All echocardiograms were obtained with a SonosTM 5500
ultrasonographic system and a 1.8–2.1/3.6–4.1 MHz S4
probe (Philips Medical Systems, Best, The Netherlands)
according to current guidelines.18 19 The echocardiographic
data were digitally stored for subsequent off-line analysis.
All TTE examinations were performed by the same operator.
Standard LV short-axis and two- and four-chamber views
were obtained from the parasternal and apical views. For
the pulsed-wave Doppler recordings of the mitral inflow,
the sample volume was positioned between the tips of the
open mitral leaflets using optimal alignment with transmitral
blood flow. For recordings of isovolumic relaxation time
(IVRT), the beam was slightly moved towards the LV
outflow tract to obtain recordings of both LV inflow and LV
outflow signals. For recordings of pulsed-wave tissue
Doppler imaging, the sample volume was placed at the
septal and lateral sides of the mitral annulus, and the acous-
tic power and the filter frequencies of the system were set to
the lowest possible values. The following variables were
measured: end-diastolic and end-systolic areas (EDA and
ESA, respectively), peak early and peak late transmitral
filling velocities (E and A, respectively), deceleration time
(DT), IVRT, early and late diastolic velocities (e′ and a′,
respectively), and peak systolic velocity (s′) of the mitral
annulus predefined as the average of the septal and lateral
mitral annulus measurements obtained by tissue Doppler
Table 1 Patient characteristics. Values are expressed as numbers
(%) or median (range). ASA, American Society of Anesthesiology
Risk Index; BMI, body mass index
Study patients (n512)
ASA class I 12 (100)
Women 7 (58)
Age (yr) 26 (19–45)
Weight (kg) 64 (55–85)
Height (cm) 169 (163–181)
BMI (kg m22) 22 (20–26)
Haemoglobin (g litre21) 142 (121–152)
Haematocrit (%) 40 (35–45)
Creatinine (mmol litre21) 63 (47–94)
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imaging. The following derived variables were calculated
from these data: fractional area change (FAC)¼[(EDA2
ESA)/EDA]×100, ratio E/A, ratio E/e′, and ratio e′/a′. In
addition, we determined the myocardial performance index
(MPI) as a measure of global cardiac function. This index,
defined as the sum of isovolumic contraction and relaxation
time divided by the ejection time, was reported by Tei and
colleagues20 to be a simple and reproducible indicator of
cardiac function and to be independent of heart rate and
arterial pressure. LV preload was estimated by EDA and E/e′
ratio (which reflects LV filling pressure); LV afterload was
assessed by the end-systolic arterial pressure–area product
(SAP×ESA).21
Analysis of systolic function focused on FAC, and analysis
of diastolic function focused on e′ and E. FAC correlates
well with LV ejection fraction;22 E and e′ reflect the early dia-
stolic filling which depends on the pressure gradient between
the atrium and ventricle, LV myocardial relaxation, and early
diastolic untwisting.19
All variables were measured at end-expiration over three
preferably consecutive cardiac cycles and averaged by one
experienced physician-echocardiographer not involved in
data acquisition and blinded to all other study data. In a pre-
vious study from our group with a similar setting, intra- and
inter-observer variability (calculated as the mean absolute
difference between two readings divided by their mean and
expressed as percentage) were 1.5–4.2% and 2.6–6.9%,
respectively.23 In the present study, we did not re-evaluate
inter- and intra-observer variability.
Statistical analysis
The sample size calculation was based on our previous
study24 estimating that a size of 12 patients would allow to
detect an increase or decrease in e′ or FAC of 20% by the
Wilcoxon signed-rank test (a,0.05 and b≥0.8).
Data are presented as median (range) or number (percen-
tage) where appropriate. Comparisons for the haemo-
dynamic and echocardiographic effects caused by
remifentanil were performed by the two-tailed Wilcoxon
signed-rank test. A P-value of ,0.05 was considered statisti-
cally significant. All statistical analyses were performed using
an SPSS for Windows 16.0 computer package (SPSS Inc.,
Chicago, IL, USA).
Results
The study was safely performed in all patients. No compli-
cations occurred during or after the study. No patient
showed signs of relevant muscle rigidity or upper airway
obstruction during remifentanil infusion. No patient reported
nausea. Patients were conscious during the study but
became obviously sedated by remifentanil at an end-organ
concentration of 2 ng ml21. However, this observation was
not reflected by decreased BIS values.
No medication to increase or decrease arterial pressure or
heart rate was administered during the study, as arterial
pressure and heart rate did not markedly change during
remifentanil infusion (Table 2).
Effects of remifentanil on LV systolic function
At baseline, systolic function was normal in all patients: FAC
was ≥52%,22 MPI≤0.33,20 and s′≥8.2 cm s21 in each
patient.25 Remifentanil at a target concentration of 2 ng
ml21 did not change the measured echocardiographic
indices of systolic function, that is, FAC, MPI, and s′ were
similar to baseline values (Table 3).
Effects of remifentanil on LV diastolic function
At baseline, there were no signs of diastolic dysfunction: e′
was ≥12.0 cm s21, E≥64 cm s21, and E/A ratio ≥1.3 in
each patient.19 Remifentanil at a target concentration of 2
ng ml21 did not induce any echocardiographic signs of dia-
stolic dysfunction, i.e. e′ was similar to baseline (P¼0.31),
and E and the E/A ratio were slightly increased (P¼0.02
and 0.03, respectively).
Effects of remifentanil on LV preload and afterload
Regarding the echocardiographic indices of LV filling, there
was a slight increase in EDA (P¼0.03) but only a trend
towards an increased E/e′ ratio (P¼0.06), which better
reflects LV filling pressure (Table 3).19 There was no difference
in the end-systolic arterial pressure–area product before and
during remifentanil infusion (P¼0.21).
Discussion
Our study found that remifentanil at a clinically relevant infu-
sion rate of 0.08–0.09 mg kg21 min21 did not impair systolic
and diastolic LV function in spontaneously breathing healthy
young surgical patients with normal heart function. The
echocardiographic indices of systolic function, that is, FAC
and s′, were not affected by remifentanil. In contrast, the
indices of diastolic function were slightly changed during
remifentanil infusion with small but statistically significant
increases in E and E/A ratio. However, the lack of any effect
Table 2 Physiological variables at baseline and during
remifentanil infusion in the 12 study patients. Values are





119 (97–145) 121 (100–146) 0.12
Mean arterial
pressure (mm Hg)
79 (67–98) 82 (69–99) 0.27
Diastolic arterial
pressure (mm Hg)
59 (51–75) 62 (52–76) 0.18
Heart rate (beats
min21)
60 (46–98) 61 (42–83) 0.16
O2 saturation (%) 98 (94–99) 99 (98–100) 0.01
Bispectral index 96 (90–98) 96 (92–98) 0.29
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on e′ calls into question the interpretation of these changes
as being indicative of improved early diastolic function.
Preload was only minimally affected by remifentanil, as indi-
cated by slightly increased EDA but insignificantly increased
E/e′ ratio. Afterload remained similar to baseline during remi-
fentanil infusion, as indicated by the unchanged end-systolic
pressure2area product. As our study was powered to assess
changes in e′ and FAC as main diastolic and systolic variables,
differences in other echocardiographic indices must be inter-
preted cautiously.
Comparison of our findings with previous reports is compli-
cated byseveral facts. First,most previous studies investigated
the effects of remifentanil in experimental designs using
human and animal heart tissue rather than in vivo.14–16 Sec-
ondly, to our knowledge, modern echocardiographic tech-
niques have not previously been used to evaluate the effects
of opioids on diastolic and systolic cardiac function in adults.
An echocardiographic study in children anaesthetized with
sevoflurane showed a decreased cardiac output by the
addition of remifentanil, mainly as a result of a decrease in
heart rate.9 Another echocardiographic study from 1986
using the inferior M-mode technique showed that naloxone,
an opioid antagonist, did not affect cardiac dimension and
function in healthy adult subjects.26 Thirdly, former in vivo
studies investigated patients with cardiac diseases and
impaired heart function or critically ill patients.5 7–8 27 28
However, in agreement with our results, remifentanil did not
impair systolic and diastolic properties of myocardial tissue
and of isolated rabbit hearts in two experimental studies.15
16 Also, in support of our findings is the fact that remifentanil
has been successfully used as an anaesthetic agent in high-
risk patients undergoing cardiac surgery, implantation of
cardiac defibrillators, and Caesarean section in the presence
of peripartal cardiomyopathy.7 29 30 These investigations and
reports showed that remifentanil provides stable haemo-
dynamic conditions even in patients with severely impaired
cardiac function.
Conflicting findings have been reported by several studies.
A porcine study found that remifentanil directly affects the
sinus node,31 thereby inducing bradycardia. Other exper-
imental studies found that remifentanil has a vasorelaxant
effect on human saphenous veins14 and radial arteries.32
Several human studies on remifentanil found cardiovascular
side-effects including severe bradycardia and hypotension
due to vasodilation.4–9 In patients with total artificial
hearts, remifentanil induced a dose-dependent decrease in
systemic arterial pressure and a decreased resistance in
arterial vessels but not in veins.8
There are several reasons that may explain the conflicting
findings including differences in the patient population,8 11
12 the study protocol,13 14 and the species.10 13 16 For
example, the effects of remifentanil on myocardial function
and haemodynamics in healthy individuals with normal
heart function, as in our study, may differ from those in criti-
cally ill or cardiac patients.7 8 11 12 Another reason for differ-
ences between the studies is that hypotension and
bradycardia seem to be particularly pronounced when a high
dose or bolus of remifentanil is administered, or during
co-administration of remifentanil together with propofol or
other anaesthetics during the induction of anaesthesia.5 9 In
our study, we did not administer remifentanil at a high dose
and administered it as the sole drug. Another reason for con-
flicting results is the use of neuromuscular blocking agents
and intermittent positive pressure ventilation in several
other studies in anaesthetized patients,5 7 8 which both
may affect cardiac function by affecting preload and after-
load.24 33 Taken together, the results from our study and
former in vitro and in vivo studies and also case reports
Table 3 Echocardiographic variables at baseline and during remifentanil infusion in the 12 study patients, and reported normal values of these
variables in healthy, awake subjects aged 20–40 yr.19 20 23 43 *Study data are expressed as median (range). P-values were calculated by the
Wilcoxon signed-rank test. †Normal values are expressed as mean (SD). N/A, not available
Baseline* Remifentanil* P-value Normal values†
Peak early transmitral filling velocity, E (cm s21) 89 (63–117) 95 (75–114) 0.02 76 (15)
Peak late transmitral filling velocity, A (cm s21) 52 (29–74) 52 (33–71) 0.53 44 (14)
Ratio E/A 1.6 (1.3–2.5) 2.0 (1.4–3.0) 0.03 1.8 (0.6)
Peak early mitral diastolic annular velocity, e′ (cm s21) 14.8 (12.0–20.4) 15.1 (12.7–21.4) 0.31 14.1 (2.7)
Peak late mitral diastolic annular velocity, a′ (cm s21) 8.1 (5.6–12.5) 8.6 (4.7–11.6) 0.53 9.1 (1.7)
Ratio e′/a′ 2.0 (1.1–3.0) 1.9 (1.2–3.2) 0.39 1.8 (0.6)
Ratio E/e′ 5.8 (4.0–7.3) 6.8 (4.6–7.6) 0.06 5.6 (1.3)
Deceleration time, DT (ms) 189 (153–263) 177 (148–257) 0.17 217 (65)
Isovolumic relaxation time, IVRT (ms) 59 (42–93) 52 (37–85) 0.07 91 (17)
Peak systolic mitral annular velocity, s′ (cm s21) 10.3 (8.2–11.7) 10.4 (7.6–12.2) 0.53 9.4 (1.4)
End-diastolic area, EDA (cm2) 16.6 (12.5–21.6) 17.2 (13.9–23.3) 0.03 18.8 (1.4)
End-systolic area, ESA (cm2) 7.5 (4.4–10.4) 7.3 (5.1–10.7) 0.30 8.5 (2.0)
Fractional area change, FAC (%) 56 (52–65) 58 (52–63) 0.37 56 (5)
End-systolic arterial pressure–area product, SAP×ESA (mm Hg cm2) 818 (540–1298) 836 (631–1293) 0.21 N/A
Myocardial performance index, MPI 0.23 (0.09–0.33) 0.20 (0.09–0.28) 0.24 0.36 (0.10)
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suggest that remifentanil at a low-dose infusion rate does not
relevantly impair myocardial systolic, diastolic LV function, or
both. However, cardiovascular side-effects may become
evident with remifentanil bolus administration or infusion at
high dose or when co-administratedwith propofol or sevoflur-
ane.5 9
Besides a pronounced analgesic effect, all opioids also
provide dosage-related sedative effects. During remifentanil
infusion in this study, patients became sedated but all
patients remained conscious and BIS values were unaffected.
Previous studies investigating the effect of remifentanil on
BIS values have yielded controversial results,6 34 35 but the
comparison with our data is complicated by the fact that in
those studies remifentanil was administered in critically ill
patients27 or co-administered with other sedatives.6 34 35As
we did not formally assess depth of sedation, conclusions
about the effect of the depth of sedation on cardiac perform-
ance are not possible from our data.
Our study has several limitations. First, the study protocol
did not include a dose–response evaluation. Safety concerns
regarding adequate respiratory drive in spontaneously
breathing patients27 and regarding haemodynamic stab-
ility4–7 kept us from administering high concentrations of
remifentanil requiring tracheal intubation and the adminis-
tration of other medication that would potentially influence
cardiac function. The investigated target concentration of 2
ng ml21 corresponds to remifentanil infusion rates that
have been used safely during surgical procedures,36 37 for
sedation on the intensive care unit,27 28 or for early post-
operative analgesia.38 Therefore, the present study gives
clinically important information on the effects of remifentanil
on LV function at a lower dose but cannot exclude different
effects at a higher dose, or after combined administration
of remifentanil together with other analgesic or anaesthetic
drugs. In addition, no conclusions must be drawn from our
findings with remifentanil to the effects of other opioids.
Secondly, spontaneous breathing during remifentanil infu-
sion and oxygen supplementation might result in elevated
concentrations of PaCO2 and PaO2 . Hypercapnia is known to
decrease systemic vascular resistance and increase stroke
volume and cardiac output,39 40 whereas hyperoxaemia
may increase systemic vascular resistance.41 Therefore,
both increased concentration of PaCO2 and PaO2 may poten-
tially influence LV filling and consequently LV function.
However, remifentanil infusion up to 0.1 mg kg21 min21 in
spontaneously breathing critically ill patients did not result
in a suppression of respiratory drive or in a relevant increase
in PaCO2 .
27 The use of an even lower remifentanil concen-
tration in our study suggests unchanged PaCO2 concen-
trations in our patients, but we do not have measurements
to confirm this. Therefore, we cannot fully exclude an
increase in PaCO2 in our patients during remifentanil adminis-
tration. Changes in PaCO2 and PaO2 are unlikely to be confoun-
ders in our study, because previous studies have found that
PaCO2 did not relevantly impair diastolic and systolic func-
tion23 40 and that PaO2 may only affect cardiac function at
very high levels.41
Thirdly, we applied a standardized infusion therapy but
could not strictly control preload and afterload, both of
which may influence echocardiographic indicators of systolic
and diastolic function.42 However, stable haemodynamics
and unchanged intracardiac pressures, as indicated by the
E/e′ ratio and the end-systolic pressure–area product,
strongly suggest that there were no relevant changes in
preload and afterload that might have confounded our
results.
Finally, it must be noted that we did not measure remifen-
tanil plasma concentrations. We used a commercially avail-
able and widely used calculated pharmacokinetic model
taking into account patient’s age, weight, height, and
gender.17 A previous study using a similar computerized
program showed that the difference between calculated
and measured remifentanil plasma concentrations may be
substantial at target concentrations ≥5 ng ml21 but much
smaller at the concentration used in the present study.6
However, we cannot completely exclude potentially substan-
tial differences between calculated and existing remifentanil
concentrations in our study patients, as we did not measure
plasma concentrations.
In conclusion, the present study found that remifentanil at
a calculated target effect-site concentration of 2 ng ml21 did
not impair systolic or diastolic cardiac function in young sur-
gical patients free from cardiac disease. These results
support previous data suggesting that remifentanil at a low
dose is a suitable drug for sedation in patients with normal
heart function undergoing monitored anaesthesia care or
on intensive care units. Further studies in patients at
cardiac risk are needed before such a conclusion is extended
to patients with pre-existing cardiac disease.
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